The use of ischemia modified albumin as a predictive and prognostic biomarker in patients with non–acetaminophen-induced acute liver failure

Authors

  • Aydin Aktas University of Health Sciences, Kanuni Training and Research Hospital, Department of Gastrointestinal Surgery, Trabzon, Türkiye
  • Orgun Gunes Izmir Katip Celebi University, Ataturk Training and Research Hospital, Department of Gastrointestinal Surgery, Izmir, Türkiye
  • Fatma Olmez Budak Inonu University, Faculty of Medicine, Department of Biochemistry, Malatya, Türkiye
  • Nilufer Diller Inonu University, Faculty of Medicine, Department of Biochemistry, Malatya, Türkiye
  • Adem Tuncer Inonu University, Faculty of Medicine, Department of General Surgery and Liver Transplant Institute, Malatya, Türkiye
  • Sami Akbulut Inonu University, Faculty of Medicine, Department of General Surgery and Liver Transplant Institute, Malatya, Tükiye
  • Mehmet Cagatay Taskapan Inonu University, Faculty of Medicine, Department of Biochemistry, Malatya, Türkiye
  • Cemalettin Aydin Inonu University, Faculty of Medicine, Department of General Surgery and Liver Transplant Institute, Malatya, Türkiye
  • Cuneyt Kayaalp Yeditepe University, Faculty of Medicine, Department of Gastrointestinal Surgery, Istanbul, Türkiye
  • Sezai Yilmaz Inonu University, Faculty of Medicine, Department of General Surgery and Liver Transplant Institute, Malatya, Türkiye

Keywords:

Acute liver failure, Liver transplantation, Ischemia modified albumin, Predictive and prognostic factors

Abstract

Aim: This study aimed to investigate to usability of ischemia modified albumin (IMA) and IMA/albumin ratio (IMAR) values in the follow-up of ALF patients. King College criteria (KCC) and Model for End-Stage Liver Disease (MELD) score are the most commonly used criteria in the follow-up of patients with acute liver failure (ALF). However, these criteria cannot always predict prognosis and the need for liver transplantation (LT).

Materials and Methods: IMA and IMAR values of 23 ALF patients and 43 healthy volunteers were measured. Then IMA and IMAR values were compared with KCC and MELD score to predict LT requirement and prognosis in ALF patients.

Results: IMA and IMAR values were significantly higher in ALF patients compared healthy volunteers (p=0.001, p=0.001; respectively). IMA and IMAR values predicted LT requirement in ALF patients such as KCC and MELD (≥30) score (p=0.006, p=0.04, p=0.001, p=0.03; respectively). IMA values were found to better than KCC in predicting mortality (p=0.008, p=0.02; respectively). MELD (≥30) score failed to predict mortality (p=0.44).

Conclusion: IMA and IMAR values can be used as diagnostic biomarkers in ALF patients. IMA is a better prognostic biomarker in the follow-up of ALF patients.

Downloads

Download data is not yet available.

Downloads

Published

2022-08-26

Issue

Vol. 29 No. 8 (2022): August

Section

Original Articles

License

Copyright (c) 2022 Annals of Medical Research

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

CC Attribution-NonCommercial-NoDerivatives 4.0

How to Cite

1.
The use of ischemia modified albumin as a predictive and prognostic biomarker in patients with non–acetaminophen-induced acute liver failure. Ann Med Res [Internet]. 2022 Aug. 26 [cited 2025 Feb. 23];29(8):846-52. Available from: http://annalsmedres.org/index.php/aomr/article/view/4236